CYP3A5

Summary

CYP3A5 (cytochrome P450 family 3 subfamily A member 5, HGNC:2638) is a protein-coding gene on chromosome 7q22.1, encoding Cytochrome P450 3A5 (P20815). A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The encoded protein metabolizes drugs as well as the steroid hormones testosterone and progesterone. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Two pseudogenes of this gene have been identified within this cluster on chromosome 7. Expression of this gene is widely variable among populations, and a single nucleotide polymorphism that affects transcript splicing has been associated with susceptibility to hypertensions. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1577 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 74 total
• Phenotypes (HPO): 4
• Druggable target: yes — 17 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000777

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2638
Approved symbol	CYP3A5
Name	cytochrome P450 family 3 subfamily A member 5
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	PCN3, P450PCN3, CP35
Ensembl gene	ENSG00000106258
Ensembl biotype	protein_coding
OMIM	605325
Entrez	1577

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 11 protein_coding, 9 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000222982, ENST00000439761, ENST00000456417, ENST00000461920, ENST00000463364, ENST00000463907, ENST00000466061, ENST00000469622, ENST00000469887, ENST00000473347, ENST00000480723, ENST00000481825, ENST00000488187, ENST00000489231, ENST00000646887, ENST00000882630, ENST00000882631, ENST00000882632, ENST00000882633, ENST00000882634, ENST00000882635, ENST00000882636, ENST00000882637, ENST00000882638

RefSeq mRNA: 4 — MANE Select: NM_000777 NM_000777, NM_001190484, NM_001291829, NM_001291830

CCDS: CCDS55134, CCDS5672

Canonical transcript exons

ENST00000222982 — 13 exons

Exon	Start	End
ENSE00001865277	99648194	99648400
ENSE00003462743	99650073	99650232
ENSE00003476604	99674533	99674585
ENSE00003476809	99660499	99660659
ENSE00003488439	99663968	99664095
ENSE00003517661	99662816	99662882
ENSE00003520008	99666952	99667065
ENSE00003567838	99676115	99676208
ENSE00003582326	99665166	99665314
ENSE00003583387	99652553	99652779
ENSE00003604856	99666601	99666689
ENSE00003620637	99679826	99679996
ENSE00003690910	99672580	99672679

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 99.55.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6883 / max 159.9341, expressed in 79 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
85112	0.6883	79

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.55	gold quality
right lobe of liver	UBERON:0001114	99.27	gold quality
liver	UBERON:0002107	98.51	gold quality
gall bladder	UBERON:0002110	98.00	gold quality
lower esophagus mucosa	UBERON:0035834	97.93	gold quality
duodenum	UBERON:0002114	97.60	gold quality
rectum	UBERON:0001052	97.20	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.06	gold quality
colonic mucosa	UBERON:0000317	96.64	gold quality
body of pancreas	UBERON:0001150	96.53	gold quality
tongue squamous epithelium	UBERON:0006919	96.45	gold quality
buccal mucosa cell	CL:0002336	95.94	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.97	gold quality
pylorus	UBERON:0001166	94.79	gold quality
mucosa of transverse colon	UBERON:0004991	94.47	gold quality
skin of abdomen	UBERON:0001416	94.46	gold quality
small intestine	UBERON:0002108	94.39	gold quality
cervix squamous epithelium	UBERON:0006922	94.30	gold quality
esophagus mucosa	UBERON:0002469	94.08	gold quality
skin of leg	UBERON:0001511	93.49	gold quality
transverse colon	UBERON:0001157	92.41	gold quality
body of stomach	UBERON:0001161	92.39	gold quality
right lung	UBERON:0002167	91.89	gold quality
pancreas	UBERON:0001264	91.82	gold quality
mucosa of stomach	UBERON:0001199	91.47	gold quality
zone of skin	UBERON:0000014	91.46	gold quality
stomach	UBERON:0000945	91.34	gold quality
left adrenal gland	UBERON:0001234	90.56	gold quality
right adrenal gland	UBERON:0001233	90.53	gold quality
right adrenal gland cortex	UBERON:0035827	90.25	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-23	yes	2585.96
E-GEOD-130473	yes	1706.34
E-GEOD-125970	yes	75.34
E-CURD-119	yes	56.07
E-MTAB-8410	yes	23.68
E-MTAB-10553	yes	21.08
E-HCAD-9	yes	9.78
E-CURD-135	no	2774.86
E-MTAB-9801	no	2.75
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, HNF4A, NR1I2, NR1I3, NR3C1, SP1, SP3, VDR, YY1

miRNA regulators (miRDB)

4 targeting CYP3A5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-329-5P	99.27	68.11	1597
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-6764-3P	98.44	67.64	1153
HSA-MIR-6824-3P	98.44	67.62	1154

Literature-anchored findings (GeneRIF, showing 40)

• genetic determinants of the CYP3A5 polymorphism (PMID:11740341)
• CYP3A5 polymorphism is associated with myeloid leukemia (PMID:11836601)
• High activity CYP3A4, but not CYP3A5, which primarily metabolizes testosterone, showed a striking association with the onset of puberty. (PMID:12692107)
• a high cytochrome P450, family 3, subfamily A, polypeptide 5 expressor allele frequency among African-Americans may contribute to a high prevalence of sodium-sensitive hypertension in this population (PMID:12754175)
• Carriers of this genotype require a high dose of tacrolimus to achieve the target concentration after liver transplantation. (PMID:15226679)
• CYP3A5 induction in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR) (PMID:15252010)
• Polymorphic CYP3A5 haplotypes reflecting high CYP3A5 protein expression were associated with increased levels of aflatoxin-albumin adducts. (PMID:15454734)
• Although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group. (PMID:15596575)
• Our results demonstrate that the CYP3A5*1 allele, previously reported as a marker for CYP3A5 expression in human kidney, is associated with increased risk for BEN, while CYP3A4*1B and CYP2D6 genotypes do not significantly modify the risk for the disease. (PMID:15708542)
• Patients with the CYP3A5*3/*3 genotype require less tacrolimus to reach target concentrations compared to those with the CYP3A5*1 allele in kidney transplantation. (PMID:15808586)
• The CYP3A5 A6986G polymorphism may be specifically associated with a decreased risk of low-grade or early stage prostate cancer (PMID:15876487)
• Renal transplant recipients who were CYP3A5*1 carriers required a higher dose of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted area under the curveof tacrolimus. (PMID:15919447)
• possible role of CYP3A5 as a genetic contributor to hypertension susceptibility (PMID:15952872)
• Individuals homozygous for defective CYP3A5 had reduced risk of developing oesophageal cancer (PMID:15978331)
• genotyping tests for defective CYP3A4/CYP3A5 haplotypes will be necessary to understand the variations in the metabolism and clinical toxicity of a wide variety of clinical drugs–REVIEW (PMID:16004554)
• CYP3A5*3 is the primary allelic variant in Chinese population. CYP3A5 genotypes are closely associated with blood CsA concentrations in hemopoietic stem cell transplant recipients. (PMID:16086282)
• Polymorphism in CYP3A5 is associated with elevated blood pressure (PMID:16141800)
• Transcription of CYP3A5 gene in leukemia cells directly induces resistance to anthracyclines and alkaloids, the cells are still sensitive to epipodophyllotoxins. (PMID:16188140)
• mRNA level of CYP3A5 is significantly lower in the ascending colon in comparison to the descending and sigmoid colon. (PMID:16253141)
• The CYP3A5*1 genotype is associated with increased saquinavir oral clearance. (PMID:16338276)
• intestinal CYP3A5, as well as hepatic CYP3A5, plays an important role in the first-pass effect of orally administered tacrolimus (PMID:16424824)
• There is a preliminary indication that the CYP3A5 genotype might affect plasma levels of budesonide. (PMID:16584389)
• analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 (PMID:16684709)
• CYP3A5*1 exhibits no significant effect on blood pressure, left ventricular mass and left ventricular geometry (PMID:16822233)
• The effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine dose adjusted trough blood concentration during the early period after renal transplantation in Chinese patients is reported. (PMID:17042920)
• Genetic polymorphisms in CYP3A5are known to influence tacrolimus (Tac) dose requirements and trough blood levels in stable transplant patients. (PMID:17049058)
• the frequency of the CYP3A5*3C null allele in French Caucasians (81.3%) and in Tunisians (80.0%) is higher than in the Gabonese population (12.5%) (p < 0.001) (PMID:17162466)
• genetic variation in CYP3A5 may predict response to tamoxifen therapy (PMID:17244352)
• there is no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1, GSTM1 and GSTT1 and outcome either after treatment with induction chemotherapy or after high-dose therapy for multiple myeloma (PMID:17296590)
• The AUC for saquinavir among individuals with two functional CYP3A5 alleles was lower than among those with no functional alleles (PMID:17329995)
• ABCB1 and CYP3A5 genes interact with urinary sodium excretion in their effect on ambulatory blood pressure, suggesting a gene-gene-environment interaction. (PMID:17372036)
• Differences exist in protein levels of certain CYPs in non-malignant esophageal tissue (e.g. CYP2C8, CYP3A4, CYP3A5, and CYP2E1) between SCC patients and healthy subjects and may contribute to the development of squamous-cell carcinoma in the esophagus. (PMID:17373732)
• Relationship between reduced presence of CYP3A5 in kidney tubules and nephrotoxicity should be further explored to elucidate role of this enzyme in mediating toxicity. (PMID:17395652)
• A possible influence of CYP3A5 polymorphism on tacrolimus pharmacodynamics. (PMID:17430486)
• CYP3A5, a highly polymorphic member of the CYP3A family, plays an important role in the metabolism of verapamil in vivo. CYP3A5 genotype is associated with variations in verapamil disposition and response in healthy volunteers. (PMID:17443134)
• CYP3A4 plays a major role in TPA023 metabolism, and CYP3A5 may also contribute at higher concentrations of the compound. (PMID:17460031)
• CYP3A5 genotype had no effect on the systemic or apparent oral clearances, or pharmacodynamics, of the CYP3A probes alfentanil and midazolam. (PMID:17554244)
• Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 different Chinese ethnic groups; close linkage is demonstrated (PMID:17582393)
• Common polymorphisms on CYP3A4 and CYP3A5 genes do not modify the risk of developing digestive cancers in Western Europe. (PMID:17605821)
• Patients carrying a CYP3A5*1 allele require a twofold higher tacrolimus dose compared with homozygous carriers of the CYP3A5*3 variant allele to maintain the target dnAUC(0-12). (PMID:17635182)

Cross-species orthologs

20 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyp3c1	ENSDARG00000015575
danio_rerio	cyp3c3	ENSDARG00000037873
danio_rerio	cyp3c2	ENSDARG00000037874
danio_rerio	cyp3c4	ENSDARG00000070021
danio_rerio	cyp3a65	ENSDARG00000103295
mus_musculus	Cyp3a25	ENSMUSG00000029630
mus_musculus	Cyp3a13	ENSMUSG00000029727
mus_musculus	Cyp3a16	ENSMUSG00000038656
mus_musculus	Cyp3a44	ENSMUSG00000054417
mus_musculus	Cyp3a11	ENSMUSG00000056035
mus_musculus	Cyp3a59	ENSMUSG00000061292
mus_musculus	Cyp3a57	ENSMUSG00000070419
mus_musculus	Cyp3a41a	ENSMUSG00000075551
mus_musculus	Cyp3a41b	ENSMUSG00000075552
rattus_norvegicus	Cyp3a18	ENSRNOG00000000969
rattus_norvegicus	Cyp3a73	ENSRNOG00000000978
rattus_norvegicus	Cyp3a62	ENSRNOG00000001379
rattus_norvegicus	Cyp3a23-3a1	ENSRNOG00000032560
rattus_norvegicus	Cyp3a9	ENSRNOG00000046643
rattus_norvegicus	Cyp3a23-3a1	ENSRNOG00000067532

Paralogs (3): CYP3A43 (ENSG00000021461), CYP3A4 (ENSG00000160868), CYP3A7 (ENSG00000160870)

Protein

Protein identifiers

Cytochrome P450 3A5 — P20815 (reviewed: P20815)

Alternative names: CYPIIIA5, Cytochrome P450-PCN3

All UniProt accessions (2): P20815, Q7Z3N0

UniProt curated annotations — full annotation on UniProt →

Function. A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH–hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2. Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione. Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance. Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine.

Subcellular location. Endoplasmic reticulum membrane. Microsome membrane.

Induction. By glucocorticoids, such as dexamethesone.

Pathway. Steroid hormone biosynthesis. Cofactor metabolism; retinol metabolism.

Miscellaneous. Chimeric transcripts, characterized by CYP3A43 exon 1 joined at canonical splice sites to distinct sets of CYP3A5 exons, have been detected. All are possibly produced by trans-splicing. The chimeric transcripts exist in 2 different combinations: CYP3A43 exon 1 joined in frame to CYP3A5 exon 11-13 and CYP3A43 exon 1 joined in frame to CYP3A5 exon 12-13. All chimeric transcripts are expressed at very low levels in the liver.

Similarity. Belongs to the cytochrome P450 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P20815-1	1	yes
P20815-2	2

RefSeq proteins (4): NP_000768, NP_001177413, NP_001278758, NP_001278759 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001128	Cyt_P450	Family
IPR002402	Cyt_P450_E_grp-II	Family
IPR008072	Cyt_P450_E_CYP3A	Family
IPR017972	Cyt_P450_CS	Conserved_site
IPR036396	Cyt_P450_sf	Homologous_superfamily
IPR050705	Cytochrome_P450_3A	Family

Pfam: PF00067

Enzyme classification (BRENDA):

• EC 1.14.14.1 — unspecific monooxygenase (BRENDA: 53 organisms, 363 substrates, 53 inhibitors, 69 Km, 40 kcat entries)

Substrate kinetics (BRENDA)

24 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
FENTHION	0.0016–0.131	18
NADH	0.004–1.43	13
NADPH	0.002–0.13	6
(1R)-CIS-PERMETHRIN	0.055–0.061	2
(1R)-TRANS-PERMETHRIN	0.115–0.131	2
(1S)-CIS-PERMETHRIN	0.057–0.063	2
(1S)-TRANS-PERMETHRIN	0.101–0.106	2
7-ETHOXYRESORUFIN	0.0001–0.0012	2
MYRISTIC ACID	0.023–0.11	2
OLEIC ACID	0.075–0.084	2
OMEGA-(P-NITROPHENYL)DECANOIC ACID	0.0064–0.0245	2
OMEGA-(P-NITROPHENYL)DODECANOIC ACID	0.0065–0.0104	2
OMEGA-(P-NITROPHENYL)OCTANOIC ACID	0.0319–0.0618	2
12-METHYL-TETRADECANOIC ACID	0.0129	1
13-METHYL-TETRADECANOIC ACID	0.0165	1

Catalyzed reactions (Rhea), 10 shown:

• an organic molecule + reduced [NADPH–hemoprotein reductase] + O2 = an alcohol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:17149)
• all-trans-retinol + reduced [NADPH–hemoprotein reductase] + O2 = all-trans-retinal + oxidized [NADPH–hemoprotein reductase] + 2 H2O + H(+) (RHEA:42092)
• testosterone + reduced [NADPH–hemoprotein reductase] + O2 = 6beta,17beta-dihydroxyandrost-4-en-3-one + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:46296)
• estrone + reduced [NADPH–hemoprotein reductase] + O2 = 2-hydroxyestrone + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47208)
• 17beta-estradiol + reduced [NADPH–hemoprotein reductase] + O2 = 2-hydroxy-17beta-estradiol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47212)
• progesterone + reduced [NADPH–hemoprotein reductase] + O2 = 6beta-hydroxyprogesterone + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47252)
• androst-4-ene-3,17-dione + reduced [NADPH–hemoprotein reductase] + O2 = 6beta-hydroxyandrost-4-ene-3,17-dione + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47256)
• 17beta-estradiol + reduced [NADPH–hemoprotein reductase] + O2 = 4-hydroxy-17beta-estradiol + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47280)
• estrone + reduced [NADPH–hemoprotein reductase] + O2 = 4-hydroxyestrone + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:47292)
• all-trans-retinoate + reduced [NADPH–hemoprotein reductase] + O2 = all-trans-4-hydroxyretinoate + oxidized [NADPH–hemoprotein reductase] + H2O + H(+) (RHEA:51984)

UniProt features (59 total): helix 24, strand 13, sequence variant 9, turn 5, sequence conflict 4, splice variant 2, chain 1, binding site 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
6MJM	X-RAY DIFFRACTION	2.2
9MS2	X-RAY DIFFRACTION	2.25
7SV2	X-RAY DIFFRACTION	2.46
7LAD	X-RAY DIFFRACTION	2.65
8SG5	X-RAY DIFFRACTION	2.8
5VEU	X-RAY DIFFRACTION	2.91

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P20815-F1	93.52	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 441 (axial binding residue)

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-211981	Xenobiotics
R-HSA-5423646	Aflatoxin activation and detoxification

MSigDB gene sets: 168 (showing top): GOBP_LIPID_MODIFICATION, MODULE_93, REACTOME_BIOLOGICAL_OXIDATIONS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_OXIDATIVE_DEMETHYLATION, GOBP_REGULATION_OF_HORMONE_LEVELS, SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN, GOBP_RETINOL_METABOLIC_PROCESS, DARWICHE_PAPILLOMA_PROGRESSION_RISK, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_DEMETHYLATION, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOBP_TOXIN_METABOLIC_PROCESS, CAIRO_HEPATOBLASTOMA_DN

GO Biological Process (11): lipid hydroxylation (GO:0002933), xenobiotic metabolic process (GO:0006805), steroid metabolic process (GO:0008202), estrogen metabolic process (GO:0008210), alkaloid catabolic process (GO:0009822), xenobiotic catabolic process (GO:0042178), retinol metabolic process (GO:0042572), retinoic acid metabolic process (GO:0042573), aflatoxin metabolic process (GO:0046222), oxidative demethylation (GO:0070989), lipid metabolic process (GO:0006629)

GO Molecular Function (13): monooxygenase activity (GO:0004497), iron ion binding (GO:0005506), retinoic acid 4-hydroxylase activity (GO:0008401), oxidoreductase activity (GO:0016491), oxygen binding (GO:0019825), heme binding (GO:0020037), testosterone 6-beta-hydroxylase activity (GO:0050649), estrogen 16-alpha-hydroxylase activity (GO:0101020), estrogen 2-hydroxylase activity (GO:0101021), protein binding (GO:0005515), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712), metal ion binding (GO:0046872)

GO Cellular Component (4): endoplasmic reticulum membrane (GO:0005789), intracellular membrane-bounded organelle (GO:0043231), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cytochrome P450 - arranged by substrate type	1
Biological oxidations	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hormone metabolic process	3
steroid hydroxylase activity	3
catabolic process	2
retinoid metabolic process	2
oxidoreductase activity	2
monooxygenase activity	2
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	2
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	2
lipid modification	1
metabolic process	1
cellular response to xenobiotic stimulus	1
lipid metabolic process	1
steroid metabolic process	1
alkaloid metabolic process	1
xenobiotic metabolic process	1
primary alcohol metabolic process	1
olefinic compound metabolic process	1
monocarboxylic acid metabolic process	1
mycotoxin metabolic process	1
demethylation	1
primary metabolic process	1
transition metal ion binding	1
catalytic activity	1
small molecule binding	1
tetrapyrrole binding	1
binding	1
cation binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
intracellular anatomical structure	1
membrane-bounded organelle	1
intracellular organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1846 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYP3A5	PPIG	Q13427	926
CYP3A5	ABCB1	P08183	914
CYP3A5	NR1I2	O75469	804
CYP3A5	SLCO1B1	Q9Y6L6	787
CYP3A5	UGT1A4	P22310	769
CYP3A5	CYB5A	P00167	751
CYP3A5	CYP2E1	P05181	739
CYP3A5	UGT1A6	P19224	734
CYP3A5	UGT1A8	Q9HAW9	731
CYP3A5	UGT2B7	P16662	726
CYP3A5	UGT1A1	P22309	726
CYP3A5	P2RY12	Q9H244	726
CYP3A5	UGT1A7	Q9HAW7	726
CYP3A5	UGT1A10	Q9HAW8	726
CYP3A5	VKORC1	Q9BQB6	720

IntAct

12 interactions, top by confidence:

A	B	Type	Score
CYP3A5	HTT	psi-mi:“MI:0915”(physical association)	0.560
CYP3A5	IGHG1	psi-mi:“MI:0914”(association)	0.530
CYP3A5	CYB5A	psi-mi:“MI:0407”(direct interaction)	0.440
CYP3A5	CALU	psi-mi:“MI:0915”(physical association)	0.400
CYP3A5	CYP3A4	psi-mi:“MI:0915”(physical association)	0.400
ETV5	CYP3A5	psi-mi:“MI:0915”(physical association)	0.370
CYP3A5	ATOH8	psi-mi:“MI:0915”(physical association)	0.370
CYP3A5	RDH13	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (14): CYP3A7 (Affinity Capture-MS), IGHG2 (Affinity Capture-MS), SERPINB4 (Affinity Capture-MS), IGHG1 (Affinity Capture-MS), CYP3A5 (Proximity Label-MS), CYP3A5 (Negative Genetic), CYP3A5 (Affinity Capture-MS), CYP3A7 (Affinity Capture-MS), IGHG1 (Affinity Capture-MS), SERPINB4 (Affinity Capture-MS), CYP3A4 (Affinity Capture-MS), RDH13 (Two-hybrid), ETV5 (Two-hybrid), CYP3A5 (Two-hybrid)

ESM2 similar proteins: A2A974, F1Q8C3, H1A988, O18993, O35728, O88833, P00186, P04799, P08516, P08684, P13584, P14579, P14581, P15128, P15129, P20815, P20816, P20817, P24453, P24462, P24463, P24464, P33268, P33274, P51869, P51871, P78329, P79102, P79401, P98187, Q00557, Q08477, Q29496, Q3MID2, Q64391, Q64462, Q64464, Q6A152, Q6NT55, Q86W10

Diamond homologs: A0A0C2W6G6, A0A1L9WQK2, A0A1V0QSE7, A0A2H3CSA7, A0A2H3CZX2, A0A3G9HRC2, A0A3S5HYN5, A0A8K1AW54, A2A974, A2RRT9, A8NCK6, B0XZV0, B8QHP5, F1SY62, F1SY74, F1SYB6, F1SYH7, F2K081, F2ZAF9, I1RE80, I1S2J5, I3PLR1, L7X3S1, O08336, O17624, O18993, O43174, O44221, O48786, O49396, O55127, O70537, O88833, P05183, P08684, P0DKI7, P0DOX0, P11372, P11707, P13584

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	14
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2441 predictions. Top by Δscore:

Variant	Effect	Δscore
7:99650068:CTGA:C	donor_loss	1.0000
7:99650070:GAC:G	donor_loss	1.0000
7:99650071:ACC:A	donor_loss	1.0000
7:99650072:C:CT	donor_loss	1.0000
7:99650252:T:TC	acceptor_gain	1.0000
7:99660655:CAGAG:C	acceptor_gain	1.0000
7:99660656:AGAG:A	acceptor_gain	1.0000
7:99660657:GAG:G	acceptor_gain	1.0000
7:99660660:C:CC	acceptor_gain	1.0000
7:99663962:TTTTA:T	donor_loss	1.0000
7:99663963:TTTA:T	donor_loss	1.0000
7:99663964:TTA:T	donor_loss	1.0000
7:99663965:TA:T	donor_loss	1.0000
7:99663966:A:AG	donor_loss	1.0000
7:99663967:C:CA	donor_loss	1.0000
7:99664093:GTA:G	acceptor_gain	1.0000
7:99664096:C:CC	acceptor_gain	1.0000
7:99665161:CATA:C	donor_gain	1.0000
7:99665164:A:AC	donor_gain	1.0000
7:99665165:C:CC	donor_gain	1.0000
7:99665168:A:AC	donor_gain	1.0000
7:99665169:T:C	donor_gain	1.0000
7:99665211:T:TA	donor_gain	1.0000
7:99665215:A:AC	donor_gain	1.0000
7:99665222:T:A	donor_gain	1.0000
7:99665313:TG:T	acceptor_gain	1.0000
7:99665315:C:CC	acceptor_gain	1.0000
7:99672676:CGTT:C	acceptor_gain	1.0000
7:99676415:G:C	donor_gain	1.0000
7:99679820:A:AC	donor_gain	1.0000

AlphaMissense

3296 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:99650184:A:C	F434L	0.998
7:99650184:A:T	F434L	0.998
7:99650186:A:G	F434L	0.998
7:99650169:T:A	R439S	0.997
7:99650169:T:G	R439S	0.997
7:99650170:C:G	R439T	0.997
7:99652681:C:A	R375S	0.997
7:99652681:C:G	R375S	0.997
7:99667006:C:A	W126C	0.997
7:99667006:C:G	W126C	0.997
7:99667008:A:G	W126R	0.997
7:99667008:A:T	W126R	0.997
7:99650170:C:A	R439I	0.996
7:99652712:C:G	R365T	0.996
7:99650176:C:T	G437E	0.995
7:99650182:C:T	G435E	0.995
7:99652711:T:A	R365S	0.995
7:99652711:T:G	R365S	0.995
7:99652721:T:A	E362V	0.995
7:99666995:C:G	R130P	0.995
7:99650229:G:C	F419L	0.994
7:99650229:G:T	F419L	0.994
7:99650231:A:G	F419L	0.994
7:99660533:A:G	L331P	0.994
7:99650185:A:C	F434C	0.992
7:99650186:A:T	F434I	0.992
7:99665296:G:C	S180R	0.992
7:99665296:G:T	S180R	0.992
7:99665298:T:G	S180R	0.992
7:99666973:G:C	F137L	0.992

dbSNP variants (sampled 300 via entrez): RS1000111953 (7:99680238 C>T), RS1000188828 (7:99654881 T>C), RS1000203154 (7:99654534 A>G), RS1000298793 (7:99663016 C>G,T), RS1000610190 (7:99678432 C>A,T), RS1000780511 (7:99670611 T>G), RS1000811433 (7:99653887 G>A,T), RS1000977865 (7:99673455 T>G), RS1001047699 (7:99666223 T>C), RS1001064188 (7:99678177 G>C), RS1001078689 (7:99665723 G>A), RS1001191704 (7:99658148 C>G,T), RS1001276904 (7:99671929 A>C), RS1001346902 (7:99673934 G>T), RS1001385686 (7:99664252 C>T)

Disease associations

OMIM: gene MIM:605325 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): essential hypertension (MONDO:0001134)

Orphanet (1): NON RARE IN EUROPE: Essential hypertension (Orphanet:243761)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0001426	Non-Mendelian inheritance
HP:0004421	Elevated systolic blood pressure
HP:0004972	Elevated mean arterial pressure
HP:0005117	Elevated diastolic blood pressure

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST002882_2	Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor	3.000000e-12
GCST005991_15	Platelet count	4.000000e-09
GCST006249_46	Serum metabolite levels	4.000000e-21
GCST006249_47	Serum metabolite levels	1.000000e-45
GCST009733_69	Urinary metabolite levels in chronic kidney disease	9.000000e-30
GCST009735_5	Urinary metabolite modules (eigenmetabolites) in chronic kidney disease	3.000000e-18
GCST012020_383	Serum metabolite levels	4.000000e-49
GCST012020_384	Serum metabolite levels	5.000000e-60
GCST012020_385	Serum metabolite levels	1.000000e-23
GCST012020_386	Serum metabolite levels	1.000000e-48
GCST012020_387	Serum metabolite levels	4.000000e-36
GCST012020_388	Serum metabolite levels	2.000000e-37
GCST012020_389	Serum metabolite levels	4.000000e-75
GCST012020_390	Serum metabolite levels	1.000000e-12
GCST012020_391	Serum metabolite levels	4.000000e-60
GCST012020_392	Serum metabolite levels	9.000000e-12

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007007	ticagrelor measurement
EFO:0004309	platelet count
EFO:0005116	urinary metabolite measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D000075222	Essential Hypertension	C14.907.489.165

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2111472 (PROTEIN FAMILY), CHEMBL2364675 (PROTEIN FAMILY), CHEMBL3019 (SINGLE PROTEIN), CHEMBL4523986 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

17 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 652,907 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL157101	KETOCONAZOLE	4	75,361
CHEMBL1136	TELITHROMYCIN	4	15,927
CHEMBL160	CYCLOSPORINE	4	168,247
CHEMBL163	RITONAVIR	4	53,773
CHEMBL269732	TACROLIMUS ANHYDROUS	4	95,168
CHEMBL451887	CARFILZOMIB	4	12,508
CHEMBL638	VORICONAZOLE	4	23,088
CHEMBL1159650	CLOBETASOL PROPIONATE	4	30,865
CHEMBL116	AMPRENAVIR	4	29,221
CHEMBL190461	CANNABIDIOL	4	26,379
CHEMBL554	LAPATINIB	4	69,326
CHEMBL584	NELFINAVIR	4	36,859
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL4068611	RELACORILANT	3	530
CHEMBL5314518	GLECIRASIB	2	24
CHEMBL4646510	COFROGLIPTIN	2	25
CHEMBL5095174	CEDIROGANT	2	66

PharmGKB: 1 entry (VIP=true, CPIC=true)

PharmGKB clinical annotations

69 annotations.

Variant	Type	Level	Drugs	Phenotypes
CYP3A51, CYP3A53	Metabolism/PK	1B	tacrolimus	Liver transplantation
CYP3A51, CYP3A53	Toxicity	3	tacrolimus	Kidney Transplantation
CYP3A51, CYP3A53	Metabolism/PK	3	nimodipine
CYP3A51, CYP3A53	Metabolism/PK	3	dextropropoxyphene
CYP3A51, CYP3A53	Toxicity	3	fentanyl	Neoplasms;Pain
CYP3A51, CYP3A53	Dosage	3	oxycodone
CYP3A51, CYP3A53	Dosage	3	sufentanil
CYP3A51, CYP3A53	Metabolism/PK	3	dabigatran
CYP3A51, CYP3A53	Metabolism/PK	3	sirolimus	Transplantation
CYP3A51, CYP3A53	Dosage	3	sirolimus
CYP3A51, CYP3A53	Dosage	3	cyclosporine	Kidney Transplantation
CYP3A51, CYP3A53	Metabolism/PK	3	cyclosporine	Kidney Transplantation
CYP3A51, CYP3A53	Toxicity	3	olanzapine	Somnolence
CYP3A51, CYP3A53	Metabolism/PK	3	everolimus	Breast Neoplasms;Heart transplantation;Kidney Neoplasms;Kidney Transplantation;Lung transplantation;Neuroendocrine Tumors
CYP3A51, CYP3A53	Toxicity	3	paclitaxel	Neoplasms;Neurotoxicity Syndromes
CYP3A51, CYP3A53	Toxicity	3	carboplatin;paclitaxel	Leukopenia;Neutropenia;Ovarian Neoplasms
CYP3A51, CYP3A53	Toxicity	4	cyclosporine;tacrolimus	Kidney Transplantation;Transplant rejection
CYP3A51, CYP3A53	Metabolism/PK	4	methadone
CYP3A51, CYP3A53	Efficacy	4	tacrolimus	Hematopoietic stem cell transplantation;Kidney Transplantation;Transplant rejection
CYP3A51, CYP3A53	Toxicity	4	tacrolimus	Nephrotoxicity
CYP3A51, CYP3A53	Metabolism/PK	4	olanzapine
CYP3A51, CYP3A53	Dosage	2A	tacrolimus	Liver transplantation
CYP3A51, CYP3A53	Efficacy,Toxicity	3	atorvastatin	Myalgia
CYP3A51, CYP3A53	Metabolism/PK	3	cilostazol
CYP3A51, CYP3A53	Metabolism/PK	3	granisetron
CYP3A51, CYP3A53	Metabolism/PK	3	midazolam
CYP3A51, CYP3A53	Metabolism/PK	3	tacrolimus	Nephrotic Syndrome
CYP3A51, CYP3A53, CYP3A5*6	Metabolism/PK	3	fentanyl	Pain;Pain;Postoperative
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Metabolism/PK	1A	tacrolimus	Heart transplantation;Hematopoietic stem cell transplantation;Kidney Transplantation;Lung transplantation
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Dosage	1A	tacrolimus	Heart transplantation;Hematopoietic stem cell transplantation;Kidney Transplantation;Liver transplantation;Lung transplantation
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Metabolism/PK	3	atazanavir;ritonavir	HIV infectious disease
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Metabolism/PK	3	atazanavir
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Efficacy,Metabolism/PK	3	maraviroc	HIV infectious disease
CYP3A51, CYP3A53, CYP3A56, CYP3A57	Metabolism/PK	3	amlodipine
rs10264272	Metabolism/PK	3	lumefantrine	Malaria
rs15524	Metabolism/PK	3	carbamazepine	Epilepsy
rs15524	Metabolism/PK	3	tacrolimus	Kidney Transplantation;Liver transplantation
rs15524	Toxicity	3	opioids	Opioid-Related Disorders

PharmGKB variants

15 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs15524	CYP3A5, ZSCAN25	3	4.00	3	tacrolimus;carbamazepine;opioids
rs776746	CYP3A5, ZSCAN25	3	6.25	62	sunitinib;atorvastatin;carbamazepine;lumefantrine;lovastatin;simvastatin;nifedipine;ondansetron;apixaban;tacrolimus
rs10264272	CYP3A5, ZSCAN25	3	0.00	8	lumefantrine
rs17161788	CYP3A5, ZSCAN25	3	1.75	1	atorvastatin
rs28383479	CYP3A5, ZSCAN25		0.00	0
rs41279854	CYP3A5, ZSCAN25		0.00	0
rs41303343	CYP3A5, ZSCAN25	4	-1.25	7	lumefantrine
rs55817950	CYP3A5, ZSCAN25		0.00	0
rs56244447	CYP3A5, ZSCAN25		0.00	0
rs72552791	CYP3A5, ZSCAN25		0.00	0
rs4646450	CYP3A5, ZSCAN25	3	4.75	1	tacrolimus
rs3800959	CYP3A5, ZSCAN25		0.00	0
rs4646453	CYP3A5, ZSCAN25		0.00	0
rs6977165	CYP3A5, ZSCAN25		0.00	0
rs4646449	CYP3A5, ZSCAN25		0.00	0

PharmGKB dosing guidelines

4 guidelines.

Source	Drug	Guideline	Dosing?	Recommendation?
CPIC	atorvastatin;fluvastatin;lovastatin;pitavastatin;pravastatin;rosuvastatin;simvastatin	Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR
CPIC	tacrolimus	Annotation of CPIC Guideline for tacrolimus and CYP3A5	yes	yes
DPWG	tacrolimus	Annotation of DPWG Guideline for tacrolimus and CYP3A5	yes	yes
RNPGx	tacrolimus	Annotation of RNPGx Guideline for tacrolimus and CYP3A4, CYP3A5	yes	yes

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP3 family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
ritonavir	Inhibition	6.92	pKi

Binding affinities (BindingDB)

5 measured of 10 human assays (10 total across all organisms); most potent 5 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	IC50	127 nM	US-9394290: Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
4-[3-[4-[[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzenesulfinamide	IC50	2300 nM	US-20250304578: NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF
4-[3-[8-[[(3S,4R)-3-fluoropiperidin-4-yl]amino]-3-(2,2,2-trifluoroethyl)indolizin-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzamide	IC50	3800 nM	US-20250304578: NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF
N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-[3-(2-methoxy-4-methylsulfonylanilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-amine	IC50	5800 nM	US-20250304578: NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF
(2S,5S,8S)-14-methoxy-5-methyl-2-(2-methylpropyl)-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	IC50	15400 nM	US-9695174: Inhibitor of breast cancer resistance protein (BCRP)

ChEMBL bioactivities

130 potent at pChembl≥5 of 174 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.92	Ki	1.2	nM	CHEMBL583090
8.70	IC50	2	nM	CLOBETASOL PROPIONATE
8.62	Ki	2.4	nM	TELITHROMYCIN
8.28	Ki	5.3	nM	CHEMBL583093
8.25	Ki	5.6	nM	CHEMBL583091
7.90	IC50	12.5	nM	KETOCONAZOLE
7.89	Ki	13	nM	RITONAVIR
7.80	IC50	16	nM	KETOCONAZOLE
7.70	IC50	20	nM	KETOCONAZOLE
7.68	IC50	21	nM	CLOBETASOL PROPIONATE
7.62	Ki	24	nM	CHEMBL583299
7.60	Ki	25	nM	CHEMBL583298
7.36	IC50	44	nM	CLOBETASOL PROPIONATE
7.11	IC50	78	nM	CLOBETASOL PROPIONATE
7.00	Kd	100	nM	CLOBETASOL PROPIONATE
6.99	IC50	103	nM	CLOBETASOL PROPIONATE
6.96	IC50	110	nM	KETOCONAZOLE
6.92	IC50	120	nM	KETOCONAZOLE
6.92	Ki	120	nM	RITONAVIR
6.85	IC50	140	nM	TACROLIMUS ANHYDROUS
6.85	IC50	141	nM	KETOCONAZOLE
6.85	IC50	140	nM	RITONAVIR
6.80	IC50	160	nM	CHEMBL3527048
6.80	IC50	160	nM	KETOCONAZOLE
6.79	IC50	162	nM	KETOCONAZOLE
6.72	Ki	190	nM	CANNABIDIOL
6.70	Ki	200	nM	AMPRENAVIR
6.69	IC50	206	nM	CEDIROGANT
6.60	IC50	251.2	nM	CHEMBL601428
6.52	IC50	300	nM	CHEMBL1863002
6.48	IC50	330	nM	CHEMBL3527048
6.44	Ki	360	nM	TACROLIMUS ANHYDROUS
6.36	IC50	439	nM	KETOCONAZOLE
6.31	IC50	490	nM	CARFILZOMIB
6.29	IC50	513	nM	KETOCONAZOLE
6.25	IC50	556	nM	CHEMBL3422028
6.24	IC50	570	nM	CHEMBL5435851
6.24	Ki	570	nM	NELFINAVIR
6.22	IC50	600	nM	CHEMBL137192
6.22	IC50	600	nM	CHEMBL2334336
6.21	Ki	610	nM	TACROLIMUS ANHYDROUS
6.20	IC50	630	nM	TACROLIMUS ANHYDROUS
6.18	Ki	660	nM	VORICONAZOLE
6.16	IC50	700	nM	CHEMBL3330409
6.14	IC50	723	nM	CHEMBL2386285
6.13	IC50	740	nM	TACROLIMUS ANHYDROUS
6.09	IC50	810	nM	CHEMBL1863056
6.09	IC50	820	nM	CHEMBL6142591
6.08	Ki	829	nM	CHEMBL2386285
6.08	IC50	830	nM	CHEMBL3605542

PubChem BioAssay actives

117 with measured affinity, of 1183 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-1,5,7,9,11,13-hexamethyl-15-[1-(1,5-naphthyridin-4-ylmethyl)azetidin-3-yl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0012	uM
Telithromycin	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0024	uM
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-1,5,7,9,11,13-hexamethyl-15-[1-[(1R)-1-(1,8-naphthyridin-4-yl)ethyl]azetidin-3-yl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0053	uM
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-1,5,7,9,11,13-hexamethyl-15-[1-(1,8-naphthyridin-4-ylmethyl)azetidin-3-yl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0056	uM
1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	1756369: Inhibition of CYP3A4/5 in human liver microsomes using Midazolam as substrate measured after 20 mins by LC-MS/MS analysis	ic50	0.0125	uM
Ritonavir	2033231: Inhibition of CYP3A-mediated metabolism in human liver microsomes	ki	0.0130	uM
1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	2099950: Inhibition of CYP3A4/5 in human liver microsomes incubated for 15 mins by LC-MS/MS analysis	ic50	0.0200	uM
Clobetasol Propionate	1529076: Inhibition of CYP3A5 in doxycycline-induced CYP3A5 overexpressing wild type human AsPC1 cells assessed as decrease in 1-hydroxymidazolam formation using midazolam as substrate pretreated with doxycycline for 24 hrs followed by incubation with compound for 24 hrs by LC-MS/MS analysis	ic50	0.0210	uM
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-15-[1-[(3-hydroxy-1,5-naphthyridin-4-yl)methyl]azetidin-3-yl]-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0240	uM
(1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-15-[1-[(3-hydroxy-1,8-naphthyridin-4-yl)methyl]azetidin-3-yl]-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone	440648: Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay	ki	0.0250	uM
8-imidazol-1-yl-5,6,7,8-tetrahydroquinoline	2022035: Inhibition of CYP450 (unknown origin)	ic50	0.0335	uM
Tacrolimus	1209595: Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1’-OH midazolam formation preincubated with compound before substrate addition by LC-MS method	ic50	0.1400	uM
1-methyl-3-[1-methyl-5-(4-methylphenyl)pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]pyrazolo[5,4-d]pyrimidine	1217207: Reversible inhibition of human CYP3A felodipine oxidase activity	ic50	0.1600	uM
Cannabidiol	1692725: Competitive inhibition of human recombinant CYP3A5 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 15 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	ki	0.1900	uM
Amprenavir	589169: Mechanism based inhibition of human cytochrome P450 3A5 measured by testosterone hydroxylation	ki	0.2000	uM
N-(4-chlorophenyl)-5-ethyl-N-methyl-3-phenyl-1,2-oxazole-4-carboxamide	2108148: Inhibition of CYP450 (unknown origin)	ic50	0.2512	uM
4-[(4-chloro-2-fluorophenyl)-pyrimidin-5-ylmethyl]-N-(4-chlorophenyl)piperazine-1-carboxamide	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	0.3000	uM
Carfilzomib	1219229: Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using midazolam as substrate preincubated with microsomes for 30 mins prior to substrate addition measured after 5 mins by LC-MS/MS analysis	ic50	0.4900	uM
4-[(E)-1-[4-(2-aminoethoxy)phenyl]-1-(4-hydroxyphenyl)but-1-en-2-yl]phenol	1203268: Inhibition of human recombinant CYP3A5 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	ic50	0.5560	uM
(3S,3aS,6aR)-2-[(2S)-2-[[2-(1-adamantyl)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(1S)-1-cyclohexyl-3-(cyclopropylamino)-2,3-dioxopropyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide	2020327: Inhibition of CYP3A (unknown origin)	ic50	0.5700	uM
Nelfinavir	589169: Mechanism based inhibition of human cytochrome P450 3A5 measured by testosterone hydroxylation	ki	0.5700	uM
(2-chlorophenyl)-(4-chlorophenyl)-pyridin-3-ylmethanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	0.6000	uM
1-(benzenesulfonyl)-4-[(4-chloro-2-fluorophenyl)-pyridin-3-ylmethyl]piperazine	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	0.6000	uM
Voriconazole	541854: Competitive inhibition of CYP3A in human liver microsomes assessed as midazolam 4-hydroxylation after 5 mins by Dixon plot analysis	ki	0.6600	uM
2-(dimethylamino)-2-(2-ethylphenyl)-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]acetamide	2119433: Inhibition of CYP450 (unknown origin)	ic50	0.7000	uM
4-[(E)-1-[4-(2-aminoethoxy)phenyl]-2-phenylbut-1-enyl]phenol	1203268: Inhibition of human recombinant CYP3A5 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	ic50	0.7230	uM
1-[(4-chlorophenyl)-pyridin-3-ylmethyl]-4-propan-2-ylsulfonylpiperazine	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	0.8100	uM
N-[(1R)-1-[1-ethyl-6-(trifluoromethyl)benzimidazol-2-yl]ethyl]pyridine-3-sulfonamide	1241584: Inhibition of CYP3A5 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	ic50	0.8300	uM
2-pyrrolidin-1-yl-N-[3-(3-sulfamoylphenyl)-1H-indazol-5-yl]-2-thiophen-3-ylacetamide	2119433: Inhibition of CYP450 (unknown origin)	ic50	0.9000	uM
(4-chloro-2-fluorophenyl)-(4-chlorophenyl)-pyridin-3-ylmethanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	0.9000	uM
cyclosporine	1209614: Reversible competitive inhibition of CYP3A-mediated 1’-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	ki	0.9800	uM
N-propan-2-yl-3-[(4-pyridin-4-ylphenyl)carbamoylamino]benzamide	645226: Inhibition of recombinant human CYP3A5 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	ic50	0.9800	uM
1-[[2-fluoro-4-(trifluoromethyl)phenyl]-pyridin-3-ylmethyl]-4-methylsulfonylpiperazine	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.0000	uM
1-[4-[(4-chloro-2-fluorophenyl)-pyridin-3-ylmethyl]piperazin-1-yl]-2,2-dimethylpropan-1-one	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.0000	uM
2-[4-(trifluoromethyl)phenyl]chromen-4-one	1860369: Inhibition of CYP450 in human HCT-116 cells assessed as 20-HETE formation in presence of arachidonic acid incubated for 15 mins by multi-enzyme assay based LC-MS/MS analysis	ic50	1.1000	uM
(4-chloro-2-fluorophenyl)-(4-propan-2-yloxyphenyl)-pyridin-3-ylmethanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	1.1000	uM
1-[(4-chloro-2-fluorophenyl)-pyridin-3-ylmethyl]-4-methylsulfonylpiperazine	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.3000	uM
(4-propan-2-yloxyphenyl)-pyridin-3-yl-[4-(trifluoromethyl)phenyl]methanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	1.4000	uM
(4-chloro-2-fluorophenyl)-pyridin-3-yl-[4-(trifluoromethyl)phenyl]methanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	1.4000	uM
3-[[4-(1H-imidazo[4,5-b]pyridin-7-yl)phenyl]carbamoylamino]-N,N-di(propan-2-yl)benzamide	645226: Inhibition of recombinant human CYP3A5 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	ic50	1.6000	uM
N-[1-[(1,2-dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino]-1-oxo-3-phenylpropan-2-yl]-4-methyl-2-[[2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide	1219244: Time-dependent inhibition of CYP3A in human liver microsomes preincubated for 30 mins with carfilzomib by LC-MS/MS analysis	ic50	1.8000	uM
[4-[(4-chloro-2-fluorophenyl)-pyridin-3-ylmethyl]piperazin-1-yl]-cyclopropylmethanone	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.8000	uM
(4-chlorophenyl)-(4-propan-2-yloxyphenyl)-pyridin-3-ylmethanol	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	1.9000	uM
tert-butyl 4-[(4-chloro-2-fluorophenyl)-pyridin-3-ylmethyl]piperazine-1-carboxylate	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.9000	uM
1-(benzenesulfonyl)-4-[(4-chlorophenyl)-pyridin-3-ylmethyl]piperazine	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	1.9000	uM
2,2-dimethyl-1-[4-[pyridin-3-yl-[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]propan-1-one	730416: Inhibition of CYP3A4/5 in human liver microsomes assessed as reduction in testosterone-beta-hydroxylation	ic50	2.3000	uM
5-[(5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-oxo-2,4,5,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one	1822697: Time dependent inhibition of recombinant human CYP3A5 using midazolam as substrate preincubated for 30 mins in presence of NADPH generating system followed by substrate addition incubated for 30 mins by LC-MS/MS analysis	ic50	2.3400	uM
4-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-N-[[(7R)-5,6,7,8-tetrahydro-1,6-naphthyridin-7-yl]methyl]cyclohexane-1,4-diamine	2124397: Inhibition of CYP450 (unknown origin)	ic50	2.5000	uM
3-[(4-chlorophenyl)-hydroxy-pyridin-3-ylmethyl]benzamide	673462: Inhibition of CYP3A4/5 in human liver microsomes	ic50	2.6000	uM
5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one	1822701: Time dependent inhibition of recombinant human CYP3A5 incubated for 30 mins in presence of NADPH generating system by LC-MS/MS analysis	ic50	2.7600	uM

CTD chemical–gene interactions

265 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Testosterone	decreases reaction, increases hydroxylation, affects cotreatment, increases expression, decreases expression (+3 more)	11
Tacrolimus	affects response to substance, affects metabolic processing, affects reaction, decreases metabolic processing, decreases methylation (+1 more)	10
Rifampin	increases expression	9
Ketoconazole	affects response to substance, increases expression, increases hydroxylation, increases oxidation, affects reaction (+4 more)	8
Cyclosporine	decreases expression, increases expression, affects metabolic processing, affects cotreatment	8
Midazolam	affects metabolic processing, increases hydroxylation, increases chemical synthesis, increases metabolic processing, decreases reaction (+1 more)	7
Aflatoxin B1	affects expression, decreases expression, increases expression, increases activity	7
Phenobarbital	affects expression, increases expression	6
Benzo(a)pyrene	decreases expression, increases expression	5
Dexamethasone	increases expression, decreases reaction, affects reaction	4
Chlorpyrifos	increases expression, affects metabolic processing	4
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	4
ochratoxin A	decreases expression, increases expression, increases response to substance	3
6 beta-hydroxytestosterone	increases chemical synthesis, increases hydroxylation, decreases reaction	3
1-hydroxymethylmidazolam	decreases reaction, increases chemical synthesis, increases hydroxylation	3
Acetaminophen	decreases expression, increases expression, affects cotreatment	3
Beclomethasone	decreases reaction, increases expression	3
Calcitriol	increases expression, affects cotreatment	3
Parathion	affects metabolic processing	3
Tamoxifen	affects metabolic processing, increases metabolic processing, increases abundance, decreases activity	3
Tetrachlorodibenzodioxin	increases expression	3
Thalidomide	increases chemical synthesis, increases metabolic processing, increases expression, increases hydroxylation	3
Alfentanil	affects metabolic processing, increases reaction, decreases reaction	3
tetrandrine	decreases abundance, increases reaction, decreases expression, increases abundance, increases expression (+2 more)	2
afimoxifene	decreases activity, increases metabolic processing, increases abundance	2
sodium arsenite	decreases expression, increases abundance, increases expression	2
N-desmethyltamoxifen	increases abundance, decreases activity, increases metabolic processing	2
fipronil	increases expression, affects cotreatment	2
Fluticasone	affects response to substance, increases metabolic processing, decreases activity, increases expression, decreases reaction	2
Clopidogrel	affects response to substance, increases cleavage, increases oxidation	2

ChEMBL screening assays

604 unique, capped per target: 585 admet, 19 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1919560	ADMET	Inhibition of CYP3A4/5-mediated testosterone 6beta-hydroxylation in human liver microsomes by LCMS analysis	Novel orally active antimalarial thiazoles. — J Med Chem
CHEMBL6077306	Binding	Time dependent inhibition of CYP3A4/5 (unknown origin) at 30 uM measured after 30 mins relative to control	Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform. — J Med Chem

Cellosaurus cell lines

5 cell lines: 3 induced pluripotent stem cell, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_UH17	HEK293 CYP3A5*1	Transformed cell line	Female
CVCL_UH18	HEK293 CYP3A5*1-V5	Transformed cell line	Female
CVCL_UM09	LSCTRi006-A	Induced pluripotent stem cell	Female
CVCL_VE29	LSCTRi001-A	Induced pluripotent stem cell	Female
CVCL_VE30	LSCTRi002-A	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00157963	PHASE4	COMPLETED	Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
NCT00295555	PHASE4	COMPLETED	Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
NCT00311155	PHASE4	COMPLETED	Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
NCT00328965	PHASE4	COMPLETED	Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
NCT00366119	PHASE4	UNKNOWN	Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
NCT00408512	PHASE4	COMPLETED	Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
NCT00438945	PHASE4	COMPLETED	The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
NCT00457483	PHASE4	COMPLETED	Nijmegen Antihypertensive Management Improvement Study
NCT00509470	PHASE4	COMPLETED	Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
NCT00654875	PHASE4	COMPLETED	Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00716950	PHASE4	UNKNOWN	Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients
NCT00741585	PHASE4	COMPLETED	Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00765947	PHASE4	COMPLETED	Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00794885	PHASE4	COMPLETED	China Stroke Primary Prevention Trial
NCT00819104	PHASE4	COMPLETED	A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
NCT00841308	PHASE4	UNKNOWN	Home Blood Pressure in Hypertension Management
NCT00890591	PHASE4	COMPLETED	Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00994617	PHASE4	UNKNOWN	Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
NCT01011660	PHASE4	UNKNOWN	Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
NCT01042392	PHASE4	COMPLETED	Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
NCT01120990	PHASE4	COMPLETED	Hybrid Blood Pressure Monitor Validation
NCT01131546	PHASE4	COMPLETED	Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
NCT01132768	PHASE4	TERMINATED	The Confirmatory Olmesartan Plaque Regression Study
NCT01180413	PHASE4	COMPLETED	Intensive Vasodilator Therapy in Patients With Essential Hypertension
NCT01241487	PHASE4	COMPLETED	A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
NCT01629225	PHASE4	UNKNOWN	GRK4 Polymorphisms Blood Pressure Response to Candesartan
NCT01825759	PHASE4	UNKNOWN	Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function
NCT02031861	PHASE4	COMPLETED	Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
NCT02058446	PHASE4	COMPLETED	PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
NCT02062645	PHASE4	COMPLETED	Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
NCT02184858	PHASE4	COMPLETED	Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
NCT02214498	PHASE4	UNKNOWN	Treatment of HYpertension: Morning Versus Evening
NCT02357615	PHASE4	UNKNOWN	Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
NCT02517866	PHASE4	COMPLETED	Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
NCT02612298	PHASE4	COMPLETED	Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
NCT02687178	PHASE4	COMPLETED	Canrenone as Add-on in Patients With Essential Hypertension
NCT03226340	PHASE4	UNKNOWN	S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT04306627	PHASE4	UNKNOWN	Effect of Atorvastatin on Carotid Intima Media Thickness
NCT05683301	PHASE4	COMPLETED	Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
NCT05843162	PHASE4	UNKNOWN	A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome